Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,461
Views
0
CrossRef citations to date
0
Altmetric
Oncology

The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States

Ashley Tabaha Bristol Myers Squibb, Princeton, NJ, USAORCID Iconhttps://orcid.org/0000-0003-3754-2703
ORCID Icon,
Brenna L. Bradyb IBM Watson Health, Cambridge, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3210-806X
ORCID Icon,
David Huggara Bristol Myers Squibb, Princeton, NJ, USAORCID Iconhttps://orcid.org/0000-0002-9037-8140
ORCID Icon,
Krutika Jariwala-Parikhb IBM Watson Health, Cambridge, MA, USA
,
Krystal Hueya Bristol Myers Squibb, Princeton, NJ, USA
,
Ronda Cophera Bristol Myers Squibb, Princeton, NJ, USA
&
Thomas William LeBlancc Duke Cancer Institute, Durham, NC, USAORCID Iconhttps://orcid.org/0000-0002-0546-7895
ORCID Icon show all
Pages 903-911 | Received 02 Feb 2022, Accepted 16 Jun 2022, Published online: 04 Jul 2022

References

  • De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
  • National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia – acute myeloid leukemia (AML); [cited 2021 Dec]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
  • O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(7):926–957.
  • Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? Hematol Am Soc Hematol Educ Program. 2016;2016(1):356–365.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Morita K, Kantarjian HM, Wang F, et al. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36(18):1788–1797.
  • MacPherson L, Dawson MA. Survival of the fittest: Darwinian selection underpins chemotherapy resistance in AML. Cell Stem Cell. 2017;21(3):291–292.
  • Pandya BJ, Chen C-C, Medeiros BC, et al. Economic and clinical burden of relapsed and/or refractory active treatment episodes in patients with acute myeloid (AML) in the USA: a retrospective analysis of a commercial payer database. Adv Ther. 2019;36(8):1922–1935.
  • Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, et al. Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol. 2016;9(1):79–89.
  • Bell JA, Galaznik A, Farrelly E, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27–33.
  • Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11(3):275–286.
  • Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52–58.
  • Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–1138.
  • Hagiwara M, Sharma A, Chung KC, et al. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21(11):1119–1130.
  • Sacks NC, Cyr PL, Louie AC, et al. Burden of acute myeloid leukemia among older, newly diagnosed patients: retrospective analysis of data from the 2010 to 2012 medicare limited data set. Clin Ther. 2018;40(5):692–703.e2.
  • Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s–80s.
  • Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–1603.
  • LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132(7):717–726.
  • Pandya BJ, Chen C-C, Medeiros BC, et al. Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database. J Manag Care Spec Pharm. 2020;26(7):849–859.
  • Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin. 2017;33(3):519–527.
  • Preussler JM, Meyer CL, Mau L, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogenic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):1021–1028.
  • Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and medicare populations. J Med Econ. 2018;21(6):556–555.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.